You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
University of Oxford researchers said they are weeks away from completing clinical validation of a coronavirus molecular test based on RT-LAMP technology.
A four-year, $5.5 million program will assess whether circulating cell-free DNA testing can improve diagnosis and outcomes for a type of EBV-associated cancer.
CareDx will use NanoString's new Human Organ Transplant panel to develop HistoMap, a gene expression profiling test to identify allograft rejection.
The biomarker profiling project is expected to enable a better understanding of how lifestyle, environment, and genetics combine to cause diseases.
Diagnostic WGS will be centralized and performed at the same Genomics England facility used in the 100,000 Genomes Project.
Nova Satra said it will use the EpiSwitch technology to develop and commercialize non-invasive breast cancer testing across 13 territories in Asia.
Numares will use its technology to advance work by Oxford researchers to create a noninvasive test to better diagnose MS.
The meta-analysis further suggested that efforts to screen and treat people at risk of developing diabetes might not be effective.
The test is based on MDNA's Mitomic technology, which enables the isolation of mitochondrial DNA in circulation that may be used as biomarkers.